This Timberwolves roster is different than the one from a year ago. That much is obvious in games, as Karl-Anthony Towns’ consistent scoring and general size is missed, as is the playmaking and ball security of guys like Kyle Anderson and Jordan McLaughlin. ADVERTISEMENT But their absences have been felt in the locker room, as well. Towns was a consistent source of positivity for the team. Anderson was one of the loudest vocal leaders. The latter can be especially difficult to replace, especially because it can be uncomfortable to speak up when things are going poorly and something needs to change. That was the position Anthony Edwards has found himself in early this season. Edwards has been praised for his leadership through his first four years on Minnesota’s roster. Mostly, that all came via positivity and example. Edwards can be coached hard, which gave the greenlight for the coaches to treat everyone else the same way. Edwards was also quick to credit his teammates around him for their contributions to the cause, and was eager and willing to spend time with and talk to anyone on the roster, players No. 1-15. He’ll also stand up for any of his teammates if the occasion ever arises. That’s why he has been so beloved in the locker room and why he was viewed as such a leader, even at his young age. ADVERTISEMENT But with Anderson’s departure, Edwards was now tasked with leading even through choppy waters. And the waves have been rather large through the first quarter of the season. Minnesota’s defense has fallen off a cliff in comparison to where it was a year ago. After never even as many as three consecutive games during the 2023-24 regular season, the Wolves endured a four-game losing skid earlier this week. At that point, words were exchanged, both publicly and privately. A halftime hash out during Minnesota’s loss Wednesday to Sacramento got the conversation rolling. Mike Conley got the dialogue started, but all indications are that Edwards was a healthy participant. Edwards noted it’s difficult to know what to say in those times. “Because you look at everybody, and everybody got a different agenda. It’s like, ‘What the (heck) am I supposed to say?’ You know what I mean?” Edwards said. “I’m trying to get better in that aspect, figure out what the hell to say to get everybody on the same agenda, because everybody right now is on different agendas. I think that’s one of the main culprits of why we’re losing, because everybody out there got their own agenda. I guess their imagination of what’s supposed to be going on, and what’s really happening.” Nickeil Alexander-Walker told reporters at Friday’s shootaround that this is the most vocal Edwards has ever been. And while the intention of everyone’s messages are pure, “sometimes it’s not always worded the right way.” ADVERTISEMENT “I think we’ve crossed that line of, ‘Man, I feel like you’re not hearing the message.’ It’s tough to be called out, because you start to feel like, ‘OK, are you saying I’m the reason?’ No one wants to be at fault,” Alexander-Walker said. “But at the end of the day, I definitely think that guys are open to hearing it better. And I think it just came from a stand point of, at a point and time in the conversation, there was a comeback. It was going back and forth now, as opposed to receiving it (and saying), ‘OK, I got you.’ That’s how it’s going to be. It’s very rare that someone is just going to be able to be called out and not have anything to say. “It’s human nature to be defensive, at the end of the day. But kind of remembering what we’re here for, and if I’m being called out, chances are I’ve got to look in the mirror and be better.” It’s a delicate dance. There has to be an environment rooted in accountability, but you also have to be sure not to lose teammates, as Jimmy Butler was criticized for doing during his short stint in Minnesota a few years ago. ADVERTISEMENT And while it’s never ideal for a team to be living through a stretch of basketball the quality of which falls significantly short of the expectation, these stretches will likely lead to growth for Edwards, if not on the court, then in the locker room. You can’t steer a ship to a title if you don’t know how to navigate turbulent tides. Day by day, loss by loss, Edwards is learning how to spin the wheel. ______________________________________________________ This story was written by one of our partner news agencies. Forum Communications Company uses content from agencies such as Reuters, Kaiser Health News, Tribune News Service and others to provide a wider range of news to our readers. Learn more about the news services FCC uses here .
Knight stops 20 shots, Florida rolls past Carolina 6-0 for 2nd win over 'Canes in as many daysNov. 25 (UPI) -- Macy's announced Monday that it would delay its full third-quarter earnings report because of an employee hiding up to $154 million in expenses, sending its stock plummeting in early trading.SUNRISE, Fla. (AP) — Spencer Knight made 20 saves, Mackie Samoskevich scored with less than a second left in the second period, and the Florida Panthers got four goals in the third to beat the Carolina Hurricanes 6-0 on Saturday and complete a two-day sweep. Aleksander Barkov, Sam Bennett, Aaron Ekblad, Evan Rodrigues and Adam Boqvist also scored for Florida, which won 6-3 at Carolina on Friday. The Panthers have won three straight — that streak following a stretch of six losses in seven games for the Stanley Cup champions. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.
NEW YORK — A familiar face will help the Jets with their general manager and coaching search. Gang Green has hired The 33rd Team, founded by former Jets General manager and senior vice president of football operations Mike Tannenbaum, to help them find candidates for their general manager and coaching vacancies, according to sources. Former Vikings general manager Rick Spielman will also help Tannenbaum identify candidates for the roles. The 33rd Team will also provide data analysis and experience to assist the Jets in seeking new leadership. The Jets fired both general manager Joe Douglas and coach Robert Saleh during this season. Owner Woody Johnson fired Saleh on Oct. 8 and Douglas on Nov. 19. Johnson will supervise both the general manager and coaching searches but will receive help from The 33rd Team and others within the Jets organization, who will also be involved in the search. Spielman was an advisor to the Commanders in 2024 in their search for the team’s new head coach and general manager. Washington ultimately hired Adam Peters as its general manager and Dan Quinn as coach. The Commanders currently have a 7-5 record and have been one of the surprise teams in the league this season. Tannebaum started with the Jets organization in 1997 as a director of player contracts. He became the team’s director of pro player development in 2000 and later the general manager and director of pro personnel from 2006-12. Tannebaum was also the last general manager to have significant success for the Jets. He was the architect of the Jets teams that went to back-to-back AFC Championships in 2009 and 2010. Since then, the Jets have missed the playoffs for 13 consecutive seasons, the longest playoff drought in North American sports. Under Tannebaum, the Jets drafted cornerstone players such as Pro Football Hall of Famer Darrelle Revis, D’Brickashaw Ferguson, and Nick Mangold. He also hired former Jets coaches Eric Mangini and Rex Ryan during his tenure as general manager. In 2012, Tannebaum was fired following the Jets 6-10 record. In 2015, Tannebaum became the Dolphins executive vice president of football operations until owner Stephen Ross fired him in 2018. The Jets previous three general managers following Tannenbaum’s departure, John Idzik Jr., Mike Maccagnan, and Douglas, all failed to make the playoffs during their tenures. Maccagnan is the only Jets general manager to record a winning record (2015) since 2010. Gang Green is officially in rebuild mode after Johnson fired Saleh and Douglas. The team entered the 2024 season with not just playoff expectations but Super Bowl aspirations. But with a 3-8 record with six games, the Jets are poised to miss the playoffs for the 14th straight season. After beginning the season 2-3, Johnson fired Saleh and made defensive coordinator Jeff Ulbrich interim coach. Johnson felt like the Jets were underachieving after calling the roster the best during his 25 seasons as owner. Since Johnson fired Saleh, the Jets are 1-5 and are tied for last place in the AFC East with the Patriots. During the bye last week, Johnson fired Douglas so the team could begin their general manager and coaching search. Douglas was in the final year of his contract, which he signed in 2019. The Jets are one of two coaching vacancies currently open. The Saints fired coach Dennis Allen on Nov. 4 following a 2-7 start. The Jets can currently interview any potential candidate who does not work for an NFL team. If they want to interview candidates currently working for any of the 32 teams, the Jets will have to wait until Jan. 5, the conclusion of the regular season. ©2024 New York Daily News. Visit nydailynews.com . Distributed by Tribune Content Agency, LLC.
NoneNew York, USA, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Neuroendocrine Tumors Market to Showcase Rapid Growth During the Study Period (2020–2034), at a CAGR of 5.1%| DelveInsight The launch of upcoming therapies such as ITM-11, CAM2029, RYZ101, CABOMETYX, ALPHAMEDIX, and others in the forecast period, rising incident population due to an increased number of endoscopic and radio-imaging studies, increasing research activities are driving neuroendocrine tumor market size. Companies such as Novartis, ITM Solucin GMBH, Camurus, Bristol Myers Squibb, Rayzebio, Exelixis, Ipsen, Takeda, and others are competing fiercely to capture the largest market sizes. DelveInsight’s latest Neuroendocrine Tumors Market Insights report includes a comprehensive understanding of current treatment practices, emerging neuroendocrine tumor drugs, market share of individual therapies, and current and forecasted neuroendocrine tumors market size from 2020 to 2034, segmented into 6MM [the United States, the EU4 (Germany, France, Italy, and Spain), and the United Kingdom]. Key Takeaways from the Neuroendocrine Tumors Market Report According to DelveInsight’s analysis, the market size of neuroendocrine tumors in the US was USD 1.5 billion in 2023. In 2023, Somatostatin analogs (SSAs) captured the highest market size of approximately USD 700 million in the US, followed by LUTATHERA . However, by 2034, radioligand treatments including approved beta emitter-radioligand therapy [LUTATHERA], and most anticipated alpha emitter-based therapies are expected to drive the overall NETs market size. The total number of incident cases of NETs in the US was nearly 29,500 cases in 2023 and is projected to increase by 2034. Prominent emerging companies working in the domain of neuroendocrine tumors, including ITM Solucin GMBH , Camurus , Bristol Myers Squibb , Rayzebio , Exelixis , Ipsen , Takeda , Radiomedix , Orano Med , Perspective Therapeutics , Elicera Therapeutics , Chimerix , Enterome , Teclison , and others, are actively working on innovative neuroendocrine tumor drugs. These novel neuroendocrine tumor therapies are anticipated to enter the neuroendocrine tumors market in the forecast period and are expected to change the market. Some of the key emerging neuroendocrine tumor treatments include ITM-11 (N.C.A. 177LU-EDOTREOTIDE), CAM2029, RYZ101 (ACTINIUM-225 DOTATATE), CABOMETYX (Cabozantinib), ALPHAMEDIX (212PB-DOTAMTATE), [212PB] VMT- -NET , ELC-100 (ADVINCE), ONC201 , EO2401 + NIVOLUMAB , TIRAPAZAMINE (TEC-001) , and others. As the field of radioligand therapy evolves, there is an exciting shift towards alpha-emitting radioisotopes. At present, only beta-emitting radioisotopes are currently approved, companies are now focusing on developing alpha-emitters. In August 2024, Exelixis announced that its supplemental New Drug Application (sNDA) for CABOMETYX has been accepted in the US for: 1) the treatment of adults with previously treated, locally advanced/unresectable or metastatic, well- or moderately differentiated pancreatic neuroendocrine tumors (pNET), and 2) the treatment of adults with previously treated, locally advanced/unresectable or metastatic, well- or moderately differentiated extra-pancreatic NET (epNET). The US Food and Drug Administration (FDA) assigned a standard review with a Prescription Drug User Fee Act (PDUFA) target action date of April 3, 2025. In July 2024 , Curium announced that it had submitted its 505(b)(2) NDA for Lutetium Lu 177 Dotatate Injection for the treatment of somatostatin receptor-positive (SSTR+) GEP-NETS. In April 2024, Novartis announced that the US FDA approved LUTATHERA for the treatment of pediatric patients 12 years and older with SSTR+ GEP-NETs, including foregut, midgut, and hindgut NETs. Discover which therapies are expected to grab the NETs market share @ Neuroendocrine Tumors Market Report Neuroendocrine Tumors Overview Neuroendocrine Tumors (NETs) are a diverse group of cancers that arise from neuroendocrine cells, which have characteristics of both nerve cells and hormone-producing cells. These tumors can develop anywhere in the body but are most commonly found in the gastrointestinal tract, pancreas, and lungs. The exact causes of neuroendocrine tumors are not fully understood, but certain factors may increase risk, including genetic syndromes like multiple endocrine neoplasia type 1 (MEN1), Von Hippel-Lindau disease, and neurofibromatosis. Other potential contributors include chronic inflammatory conditions, smoking, and exposure to certain chemicals. Symptoms of NETs can vary widely depending on the tumor's location and whether it secretes hormones. Some tumors may be asymptomatic for a long time. Common symptoms include abdominal pain, diarrhea, flushing of the skin, unexplained weight loss, and in cases of hormone-secreting tumors, symptoms related to excess hormones, such as changes in blood sugar levels or high blood pressure. Diagnosing NETs typically involves a combination of blood and urine tests to detect hormone levels, imaging studies like CT, MRI, or PET scans, and biopsies to analyze tumor tissue. Specialized tests like chromogranin A (CgA) blood tests or somatostatin receptor scintigraphy (Octreoscan) may also be used to identify neuroendocrine activity and locate tumors. Neuroendocrine Tumors Epidemiology Segmentation The neuroendocrine tumors epidemiology section provides insights into the historical and current neuroendocrine tumors patient pool and forecasted trends for the 6MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders. The neuroendocrine tumors market report proffers epidemiological analysis for the study period 2020–2034 in the 6MM segmented into: Total Incident Cases of NET Cases of NETs by Grade Stage-specific Cases of NET Cases of NETs by Site Cases of NETs by Functional Status Download the report to understand which factors are driving NETs epidemiology trends @ Neuroendocrine Tumors Epidemiological Insights Neuroendocrine Tumors Treatment Market Surgery is generally considered a first-line treatment for localized NETs. The frontline treatment for metastatic disease is somatostatin analogs, and currently, two agents are FDA-approved: SANDOSTATIN (octreotide acetate) and SOMATULINE DEPOT (lanreotide). Both somatostatin analogs provide symptomatic relief in 50% to 70% of patients and biochemical responses in 40% to 60% of patients. Traditionally, mTOR inhibitor – everolimus or sunitinib – was acknowledged as a second-line agent, but with the recent approval of PRRT (peptide receptor radionuclide therapy), the choice of second-line therapy is debatable. While GEP-NETs in children and adolescents are rare, the impact can be devastating. Advanced Accelerator Applications (AAA)/Novartis’s LUTATHERA is now the very first therapy approved specifically for use in pediatric patients with GEP-NETs. offering new hope to young patients living with this rare cancer. In January 2018, the FDA approved LUTATHERA, a radiolabeled somatostatin analog for the treatment of GEP-NETs. In April 2024, Novartis announced that the US FDA approved LUTATHERA for the treatment of pediatric patients 12 years and older with SSTR+ GEP-NETs, including foregut, midgut, and hindgut NETs. LUTATHERA is also approved in Europe for unresectable or metastatic, progressive, well-differentiated (G1 and G2), SSTR-positive GEP-NETs in adults, and in Japan for SSTR-positive NETs. All available therapies for NETs, whether monotherapy or combination, are currently leveraged to treat this complex, diverse population of patients, yet no treatment has maintained progression-free survival (PFS) indefinitely. At present, the NETs market is dominated by SSAs, however, by 2034, radioligand therapies are projected to capture the highest market share, reflecting a paradigm shift driven by their enhanced efficacy and the growing adoption of targeted treatment approaches. While LUTATHERA has primarily been used as a second-line treatment, there is a growing interest in expanding its use to first-line settings for medium- and high-risk NETs. This trend underscores the rising prominence of radioligand therapies in redefining treatment standards in the NETs space. Learn more about the market of NETs @ Neuroendocrine Tumors Treatment Neuroendocrine Tumors Emerging Drugs and Companies Some of the drugs in the pipeline include ITM-11 (ITM Isotope Technologies Munich), CABOMETYX (Exelixis/Ipsen/Takeda), CAM2029 (Camurus), AlphaMedix (Radiomedix/Orano Med), VMT- -NET (Perspective Therapeutics), and others. CABOMETYX (cabozantinib) is a small-molecule inhibitor targeting several receptor tyrosine kinases, such as VEGFRs, MET, RET, and the TAM family (TYRO3, MER, AXL). In August 2024, the FDA accepted a supplemental New Drug Application (sNDA) for cabozantinib to treat patients with advanced pancreatic neuroendocrine tumors (pNET) and extra-pancreatic neuroendocrine tumors (epNET) who have previously undergone treatment. The FDA set a PDUFA target date of April 3, 2025, for review and granted orphan drug designation for pNET. This application is supported by data from the Phase III CABINET trial, which studied CABOMETYX in these patient populations. ITM-11 (177Lu-edotreotide) , developed by ITM Isotope Technologies Munich , is a novel Targeted Radionuclide Therapy that combines two components: Edotreotide (DOTATOC), an octreotide-based somatostatin analog, and EndolucinBeta (n.c.a. lutetium-177 chloride), a low-energy beta-emitting synthetic radioisotope. It is currently under investigation in two Phase III clinical trials: COMPETE (NCT03049189) and COMPOSE (NCT04919226). COMPETE focuses on assessing ITM-11 for treating Grade 1 and Grade 2 GEP-NETs, while COMPOSE investigates its use in patients with well-differentiated high Grade 2 and Grade 3 GEP-NETs. ITM-11 was granted orphan designation for GEP-NET treatment based on Phase II data showing significant improvement in PFS. The other pipeline therapies for neuroendocrine tumors include RYZ101 (ACTINIUM-225 DOTATATE): BRISTOL MYERS SQUIBB/RAYZEBIO CAM2029: Camurus ALPHAMEDIX (212PB-DOTAMTATE): RADIOMEDIX/ORANO MED [212PB] VMT-α-NET: PERSPECTIVE THERAPEUTICS ELC-100 (ADVINCE): ELICERA THERAPEUTICS ONC201: CHIMERIX EO2401 + NIVOLUMAB: ENTEROME TIRAPAZAMINE (TEC-001): TECLISON It is more important than ever to ensure and understand supply chain and manufacturing issues of radiopharmaceuticals to stay at the forefront of radiopharmaceutical innovation, especially since a number of companies are investigating radiopharmaceuticals. Emerging key players should make sure that their product, supply, and production capabilities are adequate, and they should be prepared to meet the challenge of offering new therapeutic approaches to cancer patients who otherwise have limited options. In June 2024, BMS-RayzeBio was forced to pause a phase III trial due to an actinium shortage. Oncolytic virotherapy holds promise for cancer treatment. Oncolytic virotherapies like ELC100 (Elicera Therapeutics) and SVV-001 (Seneca therapeutics) are also being investigated for the treatment of NETs in early clinical trials. The anticipated launch of these emerging therapies are poised to transform the neuroendocrine tumors market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the neuroendocrine tumors market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about NETs clinical trials, visit @ Neuroendocrine Tumors Treatment Drugs Neuroendocrine Tumors Market Dynamics The neuroendocrine tumors market dynamics are anticipated to change in the coming years. NETs are often diagnosed at an early stage due to the hormonal symptoms they produce, allowing for timely intervention and better outcomes, and with advancements like LUTATHERA being the first therapy specifically approved for pediatric patients with GEP-NETs, along with continued research in targeted therapies such as somatostatin analogs and molecular inhibitors, there are growing opportunities for more effective and personalized treatments ; participation in clinical trials can further drive the discovery of new treatment modalities and improve patient outcomes. Furthermore, many potential therapies are being investigated for the treatment of NETs, and it is safe to predict that the treatment space will significantly impact the NETs market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate is expected to drive the growth of the NETs market in the 6MM. However, several factors may impede the growth of the neuroendocrine tumors market. Since most of the NET cases comprise GEP-NETs, the lack of awareness among healthcare professionals and the general public often leads to delayed diagnosis and treatment . GEP-NETs are a heterogeneous group of tumors with diverse clinical presentations, making it difficult to develop standardized treatment protocols. Additionally, challenges in research and development , such as limited funding and resources, hinder advancements in the field, while the complexity of diagnosing GEP-NETs increases the risk of misdiagnosis or delayed diagnosis, resulting in suboptimal treatment outcomes. Moreover, neuroendocrine tumor treatment poses a significant economic burden and disrupts patients’ overall well-being and QOL. Furthermore, the NETs market growth may be offset by failures and discontinuation of emerging therapies , unaffordable pricing , market access and reimbursement issues , and a shortage of healthcare specialists . Scope of the Neuroendocrine Tumors Market Report Neuroendocrine Tumors Therapeutic Assessment: Neuroendocrine Tumors current marketed and emerging therapies Neuroendocrine Tumors Market Dynamics: Conjoint Analysis of Emerging Neuroendocrine Tumors Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL’s views, Analyst’s views, Neuroendocrine Tumors Market Access and Reimbursement Discover more about neuroendocrine tumor drugs in development @ Neuroendocrine Tumors Clinical Trials Table of Contents Related Reports Neuroendocrine Tumors Epidemiology Forecast Neuroendocrine Tumors Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted NETs epidemiology in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan. Neuroendocrine Tumors Pipeline Neuroendocrine Tumors Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key NETs companies, including RayzeBio, Inc., Seneca Therapeutics, Vyriad, Inc., ADC Therapeutics, Eli Lilly and Company, Biotheus Inc., ImmunityBio, Inc., Chimerix, Merck Sharp & Dohme, Oryzon Genomics S.A., CSPC ZhongQi Pharmaceutical Technology, TaiRx, Inc., Betta Pharmaceuticals, Pfizer, NanOlogy LLC, Cardiff Oncology, Luye Pharma Group, Philogen, Hoffmann-La Roche, Regeneron Pharmaceuticals, among others. Gastroenteropancreatic Neuroendocrine Tumors Market Gastroenteropancreatic Neuroendocrine Tumors Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key GEP-NET companies including Novartis, Ipsen Biopharmaceuticals, Pfizer, ITM Isotopen Technologien Muenchen, Camurus AB, Hutchison Medipharma Limited, Bristol-Myers Squibb, Eisai Limite, Experior S.L., Tarveda Therapeutics, Roche Pharma A, Exelixis, Merck Sharp & Dohme Corp, Recordati Inc, Eli Lilly and Company, Genentech, Inc., Aveo Oncology Pharmaceuticals, Radiomedix, Orano Med, PharmaMar, Bayer, Trio Medicines, among others. Gastroenteropancreatic Neuroendocrine Tumors Pipeline Gastroenteropancreatic Neuroendocrine Tumors Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key GEP-NET companies, including Ascletis, Genexine, PharmAbcine, VAXIMM AG, WPD Pharmaceuticals, Accendatech USA Inc., Midatech Ltd, MediciNova, Kadmon Corporation, LLC, Istari Oncology, Inc., Bristol-Myers Squibb, Novartis, Jiangsu Hengrui Medicine, Peloton Therapeutics, Inc., Karyopharm Therapeutics, VBL Therapeutics, Nerviano Medical Sciences, Acerta Pharma BV, Basilea Pharmaceutica, DNAtrix, Inc., NanoPharmaceuticals LLC, Erasca, Inc., Oblato, Inc., OX2 Therapeutics, Crimson Biopharm Inc., Merck Sharp & Dohme LLC, Transgene, CANbridge Life Sciences Ltd., Eli Lilly and Company, Arcus Biosciences, Inc., Incyte Corporation, BerGenBio ASA, Istari Oncology, Inc., Chimerix, among others. Pancreatic Neuroendocrine Tumors Market Pancreatic Neuroendocrine Tumors Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key PNET companies including Novartis Pharmaceuticals, Pfizer, Keyrus Biopharma, Merck Sharp & Dohme LLC, Pfizer, Apices Soluciones S.L., Pharmacyclics LLC, Ipsen, among others. Oncology Conference Coverage Services DelveInsight’s Oncology Conference Coverage Services offer a thorough analysis of outcomes from major events like ASCO, ESMO, ASH, AACR, ASTRO, SOHO, SITC, the European CAR T-cell Meeting, and IASLC. This detailed examination provides businesses with essential insights for competitive intelligence and market trend forecasting, supporting the formulation of future strategies. Other Business Consulting Services Healthcare Competitive Intelligence Healthcare Licensing Services Healthcare Portfolio Management Case Study Learn how the engagement with respected KOLs bolstered the client's reputation as a leader in the pharma industry at KOL Profiling About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Connect with us on LinkedIn | Facebook | Twitter
LaBeaux 1-3 0-0 3, Walker 6-12 8-9 20, R.Felton 8-19 1-1 20, Hayes 0-6 3-4 3, Riley 4-11 1-1 9, Farell 4-7 0-0 12, Woodard 3-4 0-0 6, Soumaoro 2-2 0-0 5, Malonga 0-2 0-0 0. Totals 28-66 13-15 78. Brigham 3-4 5-7 11, Nicholson 2-3 0-0 4, Cotton 5-9 2-2 15, Franklin 2-5 0-0 5, Pierre 4-10 7-11 16, Ituka 5-10 6-8 18, Houge 6-11 3-3 15, Niagu 1-1 0-0 2. Totals 28-53 23-31 86. Halftime_East Carolina 39-37. 3-Point Goals_East Carolina 9-27 (Farell 4-6, R.Felton 3-10, Soumaoro 1-1, LaBeaux 1-2, Woodard 0-1, Riley 0-2, Walker 0-2, Hayes 0-3), Jacksonville St. 7-15 (Cotton 3-3, Ituka 2-6, Pierre 1-2, Franklin 1-3, Houge 0-1). Fouled Out_LaBeaux, Riley, Woodard. Rebounds_East Carolina 29 (Walker, R.Felton 7), Jacksonville St. 33 (Brigham, Pierre, Houge 6). Assists_East Carolina 9 (Hayes 4), Jacksonville St. 13 (Pierre 6). Total Fouls_East Carolina 21, Jacksonville St. 13.Anthony Edwards’ leadership had to take another step forward this week for Timberwolves